Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 END USER MARKET COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PIPELINE
4.4 SUPPLY CHAIN ECOSYSTEM
4.4.1 PROMINENT COMPANIES
4.4.2 SMALL & MEDIUM SIZE COMPANIES
4.4.3 END USERS
4.5 INDUSTRY INSIGHTS:
4.5.1 MICRO AND MACRO ECONOMIC FACTORS
4.5.2 KEY PRICING STRATEGIES
4.6 MARKETED DRUG ANALYSIS
4.6.1 DRUG
4.6.1.1 BRAND NAME
4.6.1.2 GENERIC NAME
4.6.2 THERAPEUTIC INDICATION
4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG
4.6.4 DRUG PRIMARY INDICATION
4.6.5 MARKET STATUS
4.6.6 MEDICATION TYPE
4.6.7 DRUG DOSAGE FORM
4.6.8 DOSAGES AVAILABILITY
4.6.9 PACKAGING TYPE
4.6.10 DRUG ROUTE OF ADMINISTRATION
4.6.11 DOSING FREQUENCY
4.6.12 DRUG INSIGHT
4.6.13 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES
4.6.13.1 FORECAST MARKET OUTLOOK
4.6.13.2 CROSS COMPETITION
4.6.13.3 THERAPEUTIC PORTFOLIO
4.6.13.4 CURRENT DEVELOPMENT SCENARIO
4.7 HEALTHCARE TARIFFS IMPACT ANALYSIS
4.7.1 OVERVIEW
4.7.2 TARIFF STRUCTURES
4.7.2.1 ASIA-PACIFIC VS. REGIONAL TARIFF STRUCTURES
4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS
4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES
4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS
4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS
4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS
4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS
4.8 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS
4.8.1.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES
4.8.1.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE
4.8.1.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM
4.8.2 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
4.8.2.1 WTO REGULATIONS ON HEALTHCARE TARIFFS
4.8.2.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN
4.8.2.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS
4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
4.8.4 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
4.9 EPIDEMIOLOGY OVERVIEW
4.9.1 INCIDENCE OF ALL CANCERS BY GENDER
4.9.2 TREATMENT RATE
4.9.3 MORTALITY RATE
4.9.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.9.5 PATIENT TREATMENT SUCCESS RATES
5 REGULATORY FRAMEWORK
5.1 REGULATORY FRAMEWORK OVERVIEW FOR THE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
5.1.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
5.1.2 REGULATORY APPROVAL PATHWAYS
5.1.3 LICENSING AND REGISTRATION
5.1.4 POST-MARKETING SURVEILLANCE
5.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES
6.1.2 GROWING ADOPTION OF THERANOSTICS IN PERSONALIZED MEDICINE
6.1.3 RISING CLINICAL DEMAND FOR ALPHA-BASED RADIOTHERAPIES
6.1.4 RISING CHRONIC DISEASE BURDEN DRIVING RADIOPHARMACEUTICAL DEMAND
6.2 RESTRAINTS
6.2.1 SUPPLY CHAIN AND SCALABILITY CHALLENGES FROM SHORT ISOTOPE HALF-LIVES
6.2.2 STRINGENT REGULATORY LANDSCAPE LIMITING MARKET FLEXIBILITY
6.2.3 SAFETY AND EXPOSURE RISKS IN RADIOPHARMACEUTICAL USE
6.3 OPPORTUNITIES
6.3.1 SURGE IN R&D ACTIVITY EXPANDING RADIOPHARMACEUTICAL APPLICATIONS
6.3.2 EXPANSION OF LU-177-PSMA THERAPY IN PROSTATE CANCER TREATMENT
6.3.3 STRATEGIC COLLABORATIONS DRIVING RADIOPHARMACEUTICAL INNOVATION
6.4 CHALLENGES
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
6.4.2 SHORTAGE OF SKILLED WORKFORCE IN NUCLEAR MEDICINE AND RADIOCHEMISTRY
7 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE
7.1 OVERVIEW
7.2 BETA EMITTERS
7.2.1 LUTETIUM-177
7.2.2 TERBIUM-161
7.3 ALPHA EMITTERS
7.3.1 ACTINIUM-225
7.3.2 LEAD -212
8 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES
8.1 OVERVIEW
8.2 REACTOR-PRODUCED ISOTOPES
8.3 GENERATOR-PRODUCED ISOTOPES
8.4 OTHERS
9 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGY
9.2.1 PROSTATE CANCER
9.2.2 NEUROENDOCRINE TUMORS
9.2.3 LIVER CANCER
9.2.4 BRAIN TUMORS
9.2.5 BREAST CANCER
9.2.6 LEUKEMIA
9.3 OTHERS
10 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE
10.1 OVERVIEW
10.2 SMALL MOLECULE LIGANDS
10.3 PEPTIDES
10.4 MONOCLONAL ANTIBODIES
10.5 OTHERS
11 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 ONCOLOGY CENTERS
11.2.2 NUCLEAR MEDICINE DEPARTMENTS
11.3 RADIOPHARMACIES
11.4 RESEARCH INSTITUTES
12 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 AUSTRALIA
12.1.3 JAPAN
12.1.4 SOUTH KOREA
12.1.5 SINGAPORE
12.1.6 INDIA
12.1.7 INDONESIA
12.1.8 PHILIPPINES
12.1.9 THAILAND
12.1.10 MALAYSIA
12.1.11 VIETNAM
12.1.12 TAIWAN
12.1.13 REST OF ASIA-PACIFIC
13 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 NOVARTIS AG
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 ECKERT & ZIEGLER
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 SHINE TECHNOLOGIES, LLC
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 ACTINIUM PHARMACEUTICALS, INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 PIPELINE PRODUCT PORTFOLIO
15.5.3 RECENT DEVELOPMENTS
15.6 ALPHA TAU MEDICAL LTD.
15.6.1 COMPANY SNAPSHOT
15.6.2 PIPELINE PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 ARICEUM THERAPEUTICS
15.7.1 COMPANY SNAPSHOT
15.7.2 PIPELINE PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 BAYER AG
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PIPELINE PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 CURIUM
15.9.1 COMPANY SNAPSHOT
15.9.2 PIPELINE PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 IONETIX CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 PIPELINE PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 ISOTOPIA
15.11.1 COMPANY SNAPSHOT
15.11.2 PIPELINE PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 LANTHEUS
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PIPELINE PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LILLY
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PIPELINE PRODUCT PORTFOLIO
15.14 NIOWAVE
15.14.1 COMPANY SNAPSHOT
15.14.2 PIPELINE PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 NMR
15.15.1 COMPANY SNAPSHOT
15.15.2 PIPELINE PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 ONCOINVENT
15.16.1 COMPANY SNAPSHOT
15.16.2 PIPELINE PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 ORANO GROUP
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PIPELINE PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 RADIOPHARM THERANOSTICS LIMITED
15.18.1 COMPANY SNAPSHOT
15.18.2 PIPELINE PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 TELIX PHARMACEUTICALS LIMITED
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PIPELINE PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 TERTHERA
15.20.1 COMPANY SNAPSHOT
15.20.2 PIPELINE PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 ASIA-PACIFIC CLINICAL TRIAL MARKET FOR ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET
TABLE 5 PENETRATION AND GROWTH PROSPECT MAPPING
TABLE 6 INCIDENCE OF CANCER BY GENDER
TABLE 7 CANCER MORTALITY RATE
TABLE 8 CANCER TREATMENT SUCCESS RATE
TABLE 9 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC REACTOR-PRODUCED ISOTOPES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC GENERATOR-PRODUCED ISOTOPES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC SMALL MOLECULE LIGANDS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC PEPTIDES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC MONOCLONAL ANTIBODIES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC RADIOPHARMACIES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC RESEARCH INSTITUTES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 43 CHINA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 CHINA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 46 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 47 CHINA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 50 CHINA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 52 AUSTRALIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 AUSTRALIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 55 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 56 AUSTRALIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 59 AUSTRALIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 61 JAPAN BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 JAPAN ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 64 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 65 JAPAN ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 68 JAPAN HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 70 SOUTH KOREA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 SOUTH KOREA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 73 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 74 SOUTH KOREA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 77 SOUTH KOREA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 79 SINGAPORE BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 80 SINGAPORE ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 82 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 83 SINGAPORE ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 86 SINGAPORE HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 88 INDIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 INDIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 91 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 92 INDIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 95 INDIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 97 INDONESIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 INDONESIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 100 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 101 INDONESIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 104 INDONESIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 106 PHILIPPINES BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 PHILIPPINES ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 109 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 110 PHILIPPINES ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 113 PHILIPPINES HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 115 THAILAND BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 THAILAND ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 118 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 119 THAILAND ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 122 THAILAND HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 124 MALAYSIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 MALAYSIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 127 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 128 MALAYSIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 131 MALAYSIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 133 VIETNAM BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 VIETNAM ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 136 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 137 VIETNAM ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 140 VIETNAM HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
TABLE 142 TAIWAN BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 TAIWAN ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)
TABLE 145 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 146 TAIWAN ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 149 TAIWAN HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 REST OF ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: MULTIVARIATE MODELLING
FIGURE 7 CURVE LINE CHART, BY ISOTOPE
FIGURE 8 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: END USER MARKET COVERAGE GRID
FIGURE 12 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 13 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 2024
FIGURE 16 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES IS EXPECTED TO DRIVE THE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 17 BETA EMITTERS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN 2025 & 2032
FIGURE 18 INCIDENCE BY CANCER SITE
FIGURE 19 CANCER MORTALITY RATE WITH CANCER SITE
FIGURE 20 DROC ANALYSIS
FIGURE 21 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, 2024
FIGURE 22 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 23 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, CAGR (2025-2032)
FIGURE 24 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, 2024
FIGURE 26 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, 2025 TO 2032 (USD THOUSAND)
FIGURE 27 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, CAGR (2025-2032)
FIGURE 28 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, 2024
FIGURE 30 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 31 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, CAGR (2025-2032)
FIGURE 32 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, 2024
FIGURE 34 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 35 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, CAGR (2025-2032)
FIGURE 36 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, LIFELINE CURVE
FIGURE 37 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, 2024
FIGURE 38 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 39 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2025-2032)
FIGURE 40 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SNAPSHOT (2024)
FIGURE 42 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)
